Oncogenically active MYD88 mutations in human lymphoma

  title={Oncogenically active MYD88 mutations in human lymphoma},
  author={Vu N. Ngo and Ryan M Young and Roland Schmitz and Sameer G Jhavar and Wenming Xiao and K. K. Lim and Holger Kohlhammer and Weihong Xu and Yandan Yang and Haishuang Zhao and Arthur L Shaffer and Paul B. Romesser and George W. Wright and John G. Powell and Andreas Rosenwald and Hans Konrad Muller-Hermelink and German Ott and Randy D. Gascoyne and Joseph M. Connors and Lisa M Rimsza and El{\'i}as Campo and Elaine S. Jaffe and Jan Delabie and Erlend Smeland and Richard I. Fisher and Rita M. Braziel and Raymond R. Tubbs and James R Cook and Denny D. Weisenburger and WingC. Chan and Louis M. Staudt},
The activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) remains the least curable form of this malignancy despite recent advances in therapy. Constitutive nuclear factor (NF)-κB and JAK kinase signalling promotes malignant cell survival in these lymphomas, but the genetic basis for this signalling is incompletely understood. Here we describe the dependence of ABC DLBCLs on MYD88, an adaptor protein that mediates toll and interleukin (IL)-1 receptor signalling, and the… CONTINUE READING
Highly Influential
This paper has highly influenced 29 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Highly Cited
This paper has 433 citations. REVIEW CITATIONS


Publications citing this paper.
Showing 1-10 of 249 extracted citations

Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.

Neuropathology : official journal of the Japanese Society of Neuropathology • 2017
View 17 Excerpts
Highly Influenced

IRAK signalling in cancer

British Journal of Cancer • 2015
View 9 Excerpts
Highly Influenced

434 Citations

Citations per Year
Semantic Scholar estimates that this publication has 434 citations based on the available data.

See our FAQ for additional information.


Publications referenced by this paper.
Showing 1-10 of 27 references

MLN 4924 , a NEDD 8activating enzyme inhibitor , is active in diffuse large B - cell lymphoma models : rationale for treatment of NFk Bdependent lymphoma

M. A. Milhollen
Blood • 2010

Oncogenic activation of NF-kappaB.

Cold Spring Harbor perspectives in biology • 2010

rationale for treatment of NF-kBdependent lymphoma

Milhollen, M. A. et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models
Blood 116, 1515–1523 • 2010